Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation
therapy in treating patients with non-small cell lung cancer that has spread to other places
in the body (advanced) and cannot be removed by surgery (unresectable). Immunotherapy with
monoclonal antibodies such as atezolizumab may help the body's immune system attack the
cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy
with monoclonal antibodies such as varlilumab may induce changes in body?s immune system and
may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high
energy x-rays to kill tumor cells and shrink tumors. Giving atezolizumab, varlilumab, and
radiation therapy may increase the amount of time the disease is not active or does not
spread to another part of the body.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborator:
National Cancer Institute (NCI)
Treatments:
Antibodies, Monoclonal Atezolizumab Immunoglobulin G Immunoglobulins